Please find all related articles below.
EPHA welcomes the Commission’s revision of the guidelines on Impact Assessment (IA) and the opportunity to contribute to this process via consultation. EPHA is able to offer suggestions for improving the way health impacts of EU policy are evaluated, and we highlight the need for IA to take account of the impact of EU policy upon NGOs and other third sector bodies. EPHA does not claim to have expertise in the practices of IA methodology, but rather has experience in the growing use of (...)
EPHA welcomes the Commission’s publication of comprehensive consultation guidelines. Smart regulation should mean fair and citizen-centred policy making that brings tangible benefits to the citizens of Europe and improves their quality of life. This involves greater use of evidence-based impact assessment and improving the consultation process.
The aim of the guidelines should be to ensure transparency and representativeness. Publishing consultation responses, as well as explanations (...)
Frans Timmermans performed very well in his hearing, seeming to convince the European Parliament that he was the right person to take on the designated portfolio. He presented himself as a pragmatic person. Responding to the question of MEP In’t Veld (Dutch liberal) whether he would be the “lapdog of governments or the champion of citizen’s rights”, Mr Timmermans replied that he would want to cooperate with everybody. His vision is to have a network of institutions, (...)
Below you can find EPHA’s response to the public consultation on the mid-term review of the Europe 2020 Strategy. EPHA believes that the Europe 2020 Strategy should be revised in order to better serve the public health interests of Europeans. Current targets do not invest enough in sustainable development despite its potential to create economic surplus in addition to social benefits. EPHA advocates the addition of more health targets in the Europe 2020 Strategy as well as more (...)
“Placing pharma policy in DG Enterprise was justified. It has traditionally been in DG Enterprise, but was moved to DG Sanco and has once again been instated as an Enterprise competence” said during her hearing Commissioner-designate Elzbieta Bienkowska.
By Dorota Sienkiewicz,Health Equity and Policy Coherence Coordinator, and Martyna Giedrojć, EPHA Policy Officer for Health Systems
The pharmaceutical industry is the biggest sector in the world. In terms of production, (...)
Brussels, 2 October 2014 - We are writing to support Member States who have already expressed their concerns on the decision of European Commission President Elect Jean-Claude Juncker to move the competence for medicinal products and health technologies from the Commissioner in charge of Health to the Commissioner in charge of Internal Market and Industry within the new Commission. We would like to ask for your full support to have that decision reversed.
Dear Head of States, Dear Prime (...)
Elżbieta Bieńkowska (born on 4 February 1964 in Katowice, Poland) became the Minister of Regional Development in the Cabinet of the Prime Minister Donald Tusk between 2007 and 2013 in Poland. She was then appointed a Deputy Prime Minister and carried out her mandate at the Ministry of Infrastructure and Development. In 2014 she has been nominated by the Polish government for European Commissioner who has received the Internal Market, Industry, Entrepreneurship and SMEs portfolio (...)
PHIL HOGAN (54) born in Kilkenny, Ireland, is an Irish conservative politician who was nominated as Agriculture Commissioner in September 2014 after having previously served as Minister for the Environment, Community and Local Government. As part of his designated responsibilities (as indicated by new European Commission’s President Mr Juncker in his mission letter), Mr Hogan’s responsibilities will include issues related to food security, sustainable development of (...)
The president of the European Parliament has called for a "satisfactory response" from Mr Juncker before the commissioner hearings begin. MEPs from several political groups and the Belgian Minister of Health joined the public health community in calling for medicinal products and health technology to be moved back in to the health portfolio of the European Commission. This adds to the voices of European and global players representing various branches of healthcare that expressed concerns (...)
Brussels, 16 September 2014 - We are writing to express our astonishment and concern regarding your decision to move the competence for medicinal products and health technologies from the Commissioner in charge of Health to the Commissioner in charge of internal market and industry within the new Commission.
Dear Mr Jean-Claude Juncker, President-elect of the European Commission,
The economic crisis, the ageing of the population, technological advances, and new health threats, including (...)